Blood test may predict bone disease severity
NCT ID NCT02868645
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether a protein called periostin is higher in the blood of people with fibrous dysplasia, a rare bone disease that can cause pain and fractures. Researchers will take blood samples from 65 patients and compare periostin levels to how many bones are affected and how severe the disease is. The goal is to see if a simple blood test could help doctors understand the disease better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward a simple blood test to gauge how severe a patient's fibrous dysplasia is.
- What could go wrong
- This is a small, observational study with only 65 participants. It does not test any treatment, so it may not lead to any direct benefit for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
65 people
The number who actually took part.
- Started
-
May 2016
- Finished
-
Apr 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients with fibrous dysplasia of the bone * access to social security * informed consent Exclusion Criteria: * no informed consent * pregnancy * patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis…)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone fibrous dysplasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de rhumatologie Pavillon F - Hôpital Edouard Herriot
Lyon, 69437, France